Influenza Medication Market

Influenza Medication Market (Product: Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Influenza Medication Market Outlook 2031

  • The global industry was valued at US$ 907.0 Mn in 2022
  • It is estimated to grow at a CAGR of 2.2% from 2023 to 2031 and reach US$ 1.1 Bn by the end of 2031

Analyst Viewpoint

Heightened number of influenza cases is fostering a need for reliable medications to manage symptoms and offer long-term care to patients, a majority of whom may be kids or the elderly. This is augmenting influenza medication market size. Surge in healthcare expenses accompanied by productivity losses make affordable and effective treatment options a necessity. Thus, increase in research spending on influenza management drugs, especially post the COVID-19 pandemic, is driving market development.

Prominent players operating in the global influenza medication market are investing in R&D of novel drugs for relief or treatment of associated symptoms and illnesses. Leading players are also working on Influenza treatment options for pregnant women and people with compromised immune systems.

Influenza Medication Market

Market Introduction

Influenza, commonly known as the flu, is an infectious disease caused by the influenza virus. It is highly contagious, causing severe illness and even death, especially among the people at high risk.

Pregnant women, people with compromised immune systems, and the geriatric population are the demographic that is at high risk of developing severe symptoms of influenza. Symptoms of the disease include cold, fever, cough, and sore throat, and can range from severe to mild. However, most people recover fully in a few days.

According to the World Health Organization (WHO), approximately 1 billion cases of seasonal influenza are recorded annually, with around 290,000 to 650,000 deaths caused by the virus. The influenza medication market is boosted by the production and application of seasonal vaccines and antiviral medicines.

Government efforts in raising awareness about the disease, its symptoms, and treatment is creating lucrative influenza medication market opportunities for companies operating in the industry. Constant innovations in cold and flu remedies are also augmenting market expansion.

Rise in Prevalence of Influenza Cases Driving Market Progress

Influenza virus spreads rapidly, making the disease highly contagious and prevalent among the population. Rise in prevalence of the disease has led to an urgent need for effective medications to manage symptoms and offer long-term care.

A characteristic of the virus is its tendency to undergo frequent genetic changes, forming newer strains that can counter antiviral treatments and challenge the immune system. According to the Centre for Disease Control and Prevention, around 200 pediatric deaths were recorded due to influenza across the U.S. during 2019–2020.

Surge in healthcare expenses, rise in hospitalizations, and productivity losses that accompany a severe influenza bout make effective and reliable treatment options a necessity, thus augmenting the influenza medication market growth.

Increase in Spending on Research and Vaccine Development Fueling Influenza Medication Market Growth

Influenza virus is constantly evolving, creating a dynamic environment where ongoing research is required to identify new strains and enhance the efficiency of existing treatments. Research plays a vital role in the development of vaccines and antiviral remedies for influenza management. Thus, increase in spending on research and vaccine development is fostering expansion of the influenza medication industry.

Post-pandemic spending on research and development of treatment facilities and techniques to curb another viral outbreak has increased across the globe, as both government and corporations are weary of social and economic distress.

According to a report by the International Monetary Fund, R&D of a successful vaccine can range from US$ 200 Mn to 500 Mn, with manufacturing infrastructure at scale adding another half a billion at minimum.

Regional Outlook

According to the latest influenza medication market analysis, North America held the largest share of the global landscape in 2022. Surge in adoption of advanced drug therapies and increase in healthcare expenditure are augmenting the market dynamics of the region.

Growth in awareness campaigns is leading to a gradual decline in cases of influenza in Europe. However, the prevalence rate of the disease is still high. Therefore, the influenza medication market share of the region is high.

According to the latest influenza medication industry forecast, the industry in Asia Pacific is projected to grow at a steady pace from 2023 to 2031. Increase in cases of influenza, led by the presence of a vast percentage of population prone to infectious diseases in developing economies such as China and India, is boosting the influenza medication market demand in the region.

Analysis of Key Players

Prominent influenza medication manufacturers are investing significantly in the development of antigenic drift and shift medications to provide relief or treatment options for influenza. Several symptomatic relief pharmaceuticals and influenza management products are in different phases of clinical trials.

F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Mylan, Inc., GlaxoSmithKline plc, Daiichi Sankyo Company, and Natco Pharma are key companies operating in the global landscape.

The influenza medication market research report covers these key players in terms of parameters such as company overview, product portfolio, business strategies, financial overview, and business segments.

Key Developments

  • In November 2023, Mylab announced it had entered into a strategic partnership with Ekincare to promote an anti-influenza nasal vaccine. The partnership allows the companies to include the vaccine, developed by the Serum Institute of India (SII), in their healthcare plans, thus ensuring the vaccine reaches a large demographic base.

Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 907.0 Mn
Market Forecast Value in 2031 US$ 1.1 Bn
Growth Rate (CAGR) 2.2%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Mn/Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Market Segmentation
  • Product Type
    • Zanamivir
    • Oseltamivir
    • Peramivir
    • Amantadine
    • Rimantadine
    • Inosine
    • Others (Laninamivir Octanoate, etc.)
  • Distribution Channel
    • Hospitals
    • Clinics
    • Pharmacies
    • Others
Companies Profiled
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Mylan, Inc.
  • GlaxoSmithKline plc
  • Daiichi Sankyo Company
  • Natco Pharma
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the global influenza medication market in 2022?

It was valued at US$ 907.0 Mn in 2022

How is the influenza medication business expected to grow by 2031?

It is projected to grow at a CAGR of 2.2% from 2023 to 2031

What are the key factors driving the demand for influenza medication?

Need for reliable medications to manage symptoms and offer long-term care; and increase in spending on research and vaccine development

Which influenza medication product segment held the largest share in 2022?

The oseltamivir product segment held the largest share in 2022

Which was the major region in the global influenza medication industry in 2022?

North America dominated the global landscape in 2022

Who are the key influenza medication manufacturers?

F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Mylan, Inc., GlaxoSmithKline plc, Daiichi Sankyo Company, and Natco Pharma

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Influenza Medication Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Influenza Medication Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. COVID-19 Pandemic Impact on Industry

    6. Influenza Medication Market Analysis and Forecast, by Product Type

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Product Type, 2017–2031

            6.3.1. Zanamivir

            6.3.2. Oseltamivir

            6.3.3. Peramivir

            6.3.4. Amantadine

            6.3.5. Rimantadine

            6.3.6. Inosine

            6.3.7. Others (Laninamivir Octanoate, etc.)

        6.4. Market Attractiveness, by Product Type

    7. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Distribution Channel, 2023–2031

            7.3.1. Hospitals

            7.3.2. Clinics

            7.3.3. Pharmacies

            7.3.4. Others

        7.4. Market Attractiveness, by Distribution Channel

    8. Global Influenza Medication Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2017–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Influenza Medication Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Product Type, 2017–2031

            9.2.1. Zanamivir

            9.2.2. Oseltamivir

            9.2.3. Peramivir

            9.2.4. Amantadine

            9.2.5. Rimantadine

            9.2.6. Inosine

            9.2.7. Others (Laninamivir Octanoate, etc.)

        9.3. Market Value Forecast, by Distribution Channel, 2017–2031

            9.3.1. Hospitals

            9.3.2. Clinics

            9.3.3. Pharmacies

            9.3.4. Others

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Product Type

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Influenza Medication Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product Type, 2017–2031

            10.2.1. Zanamivir

            10.2.2. Oseltamivir

            10.2.3. Peramivir

            10.2.4. Amantadine

            10.2.5. Rimantadine

            10.2.6. Inosine

            10.2.7. Others (Laninamivir Octanoate, etc.)

        10.3. Market Value Forecast, by Distribution Channel, 2017–2031

            10.3.1. Hospitals

            10.3.2. Clinics

            10.3.3. Pharmacies

            10.3.4. Others

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Product Type

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Influenza Medication Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product Type, 2017–2031

            11.2.1. Zanamivir

            11.2.2. Oseltamivir

            11.2.3. Peramivir

            11.2.4. Amantadine

            11.2.5. Rimantadine

            11.2.6. Inosine

            11.2.7. Others (Laninamivir Octanoate, etc.)

        11.3. Market Value Forecast, by Distribution Channel, 2017–2031

            11.3.1. Hospitals

            11.3.2. Clinics

            11.3.3. Pharmacies

            11.3.4. Others

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Product Type

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Influenza Medication Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product Type, 2017–2031

            12.2.1. Zanamivir

            12.2.2. Oseltamivir

            12.2.3. Peramivir

            12.2.4. Amantadine

            12.2.5. Rimantadine

            12.2.6. Inosine

            12.2.7. Others (Laninamivir Octanoate, etc.)

        12.3. Market Value Forecast, by Distribution Channel, 2017–2031

            12.3.1. Hospitals

            12.3.2. Clinics

            12.3.3. Pharmacies

            12.3.4. Others

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Product Type

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Influenza Medication Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product Type, 2017–2031

            13.2.1. Zanamivir

            13.2.2. Oseltamivir

            13.2.3. Peramivir

            13.2.4. Amantadine

            13.2.5. Rimantadine

            13.2.6. Inosine

            13.2.7. Others (Laninamivir Octanoate, etc.)

        13.3. Market Value Forecast, by Distribution Channel, 2017–2031

            13.3.1. Hospitals

            13.3.2. Clinics

            13.3.3. Pharmacies

            13.3.4. Others

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Product Type

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. F. Hoffmann-La Roche Ltd.,

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Teva Pharmaceutical Industries Ltd.

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. Sandoz International GmbH

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. Sun Pharmaceutical Industries Ltd.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. Mylan, Inc.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. GlaxoSmithKline plc

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            14.3.7. Daiichi Sankyo Company

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. Natco Pharma

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

    List of Tables

    Table 01: Global Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 02: Global Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 03: Global Influenza Medication Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 05: North America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 06: North America Influenza Medication Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 08: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 11: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 12: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 14: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 15: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 17: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 18: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031

    Figure 02: Global Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 03: Global Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 04: Global Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 05: Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 06: Global Influenza Medication Market Value Share Analysis, by Region, 2022 and 2031

    Figure 07: Global Influenza Medication Market Attractiveness Analysis, by Region, 2023–2031

    Figure 08: North America Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031

    Figure 09: North America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 10: North America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 11: North America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 12: North America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 13: North America Influenza Medication Market Value Share Analysis, by Country, 2022 and 2031

    Figure 14: North America Influenza Medication Market Attractiveness Analysis, by Country, 2023–2031

    Figure 15: Europe Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031

    Figure 16: Europe Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 17: Europe Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 18: Europe Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 19: Europe Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 20: Europe Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 21: Europe Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 22: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031

    Figure 23: Asia Pacific Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 24: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 25: Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 26: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 27: Asia Pacific Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 28: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Latin America Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031

    Figure 30: Latin America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 31: Latin America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 32: Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 33: Latin America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 34: Latin America Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 35: Latin America Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 36: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, 2023–2031

    Figure 37: Middle East & Africa Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 38: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Product Type, 2023–2031

    Figure 39: Middle East & Africa Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 40: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 41: Middle East & Africa Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 42: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 43: Global Influenza Medication Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved